Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

Octreotide

1996 • 956 citations

Dimerization of the Extracellular Domain of the Human Growth Hormone Receptor by a Single Hormone Molecule

1991 • 879 citations

Rational Design of Potent Antagonists to the Human Growth Hormone Receptor

1992 • 633 citations

Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly¹

1998 • 599 citations

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients

1998 • 365 citations

Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly

1998 • 339 citations

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

1999 • 294 citations

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

1998 • 285 citations

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1995 • 246 citations

Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol

1996 • 245 citations

Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide

1991 • 234 citations

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure

1996 • 200 citations

Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice.

1990 • 196 citations

Volume of Pituitary Macroadenomas

1992 • 194 citations

Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly¹

1997 • 181 citations

Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide¹

1997 • 177 citations

Sandostatin LAR in Acromegalic Patients: Long Term Treatment

1997 • 174 citations

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

1999 • 165 citations

Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients

1996 • 149 citations

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238]

1995 • 122 citations

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

1998 • 99 citations

Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide

1997 • 99 citations

Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly

1997 • 99 citations

Acromegaly: Diagnosis and Therapy

1989 • 90 citations

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients

1998 • 86 citations

Sandostatin LAR in Acromegalic Patients: Long Term Treatment

1997 • 62 citations

The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin Receptor

1999 • 61 citations

The Role of Radiotherapy in Acromegaly

1997 • 40 citations

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1991 • 39 citations

Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist

1997 • 30 citations

A prospective multicenter octreotide dose response study in the treatment of acromegaly

1995 • 22 citations

The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin Receptor

1999 • 20 citations

The Role of Radiotherapy in Acromegaly

1997 • 19 citations